VR Adviser LLC Reduces Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

VR Adviser LLC cut its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 32.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,952,371 shares of the company's stock after selling 1,447,629 shares during the quarter. 4D Molecular Therapeutics comprises about 1.1% of VR Adviser LLC's holdings, making the stock its 21st biggest holding. VR Adviser LLC owned about 6.39% of 4D Molecular Therapeutics worth $16,445,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in FDMT. Peapod Lane Capital LLC bought a new position in shares of 4D Molecular Therapeutics in the 4th quarter worth about $806,000. Rhumbline Advisers lifted its position in 4D Molecular Therapeutics by 5.3% during the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock valued at $409,000 after acquiring an additional 3,675 shares during the period. Proficio Capital Partners LLC lifted its position in 4D Molecular Therapeutics by 100.0% during the 4th quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company's stock valued at $111,000 after acquiring an additional 10,000 shares during the period. M&T Bank Corp lifted its position in 4D Molecular Therapeutics by 98.9% during the 4th quarter. M&T Bank Corp now owns 37,487 shares of the company's stock valued at $209,000 after acquiring an additional 18,639 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in 4D Molecular Therapeutics during the 4th quarter valued at about $629,000. 99.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on FDMT. Weiss Ratings reissued a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday, May 10th. Bank of America lowered their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Barclays lowered their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. Chardan Capital lowered their price target on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, The Goldman Sachs Group lowered their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $29.56.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock traded down $0.11 during trading hours on Friday, reaching $3.49. The company had a trading volume of 388,478 shares, compared to its average volume of 836,140. The business has a fifty day moving average price of $3.25 and a 200-day moving average price of $4.94. 4D Molecular Therapeutics, Inc. has a one year low of $2.24 and a one year high of $28.93. The firm has a market cap of $161.67 million, a PE ratio of -1.22 and a beta of 2.87.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). Equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.